Assessing CARsgen Therapeutics Holdings’s Valuation After Full Year 2025 Results And Narrowed Net Loss

Simply Wall St.03-19

CARsgen Therapeutics Holdings (SEHK:2171) moved after releasing full year 2025 results, reporting sales of CN¥125.66 million and a net loss of CN¥97.86 million, along with updated corporate governance...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620222709?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-19 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620222709","market":"us","top_or_hot":-1,"title":"Assessing CARsgen Therapeutics Holdings’s Valuation After Full Year 2025 Results And Narrowed Net Loss","media":"Simply Wall St.","content":"<div>\n<p>CARsgen Therapeutics Holdings (SEHK:2171) moved after releasing full year 2025 results, reporting sales of CN¥125.66 million and a net loss of CN¥97.86 million, along with updated corporate governance...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdingss-valuation-after-ful\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing CARsgen Therapeutics Holdings’s Valuation After Full Year 2025 Results And Narrowed Net Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing CARsgen Therapeutics Holdings’s Valuation After Full Year 2025 Results And Narrowed Net Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-19 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdingss-valuation-after-ful><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CARsgen Therapeutics Holdings (SEHK:2171) moved after releasing full year 2025 results, reporting sales of CN¥125.66 million and a net loss of CN¥97.86 million, along with updated corporate governance...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdingss-valuation-after-ful\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdingss-valuation-after-ful","article_id":"2620222709","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdingss-valuation-after-ful","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620222709","pubTimestamp":1773932711,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CARsgen Therapeutics Holdings (SEHK:2171) moved after releasing full year 2025 results, reporting sales of CN¥125.66 million and a net loss of CN¥97.86 million, along with updated corporate governance proposals announced the same day.\nSee our latest analysis for CARsgen Therapeutics Holdings.\nThe earnings release and governance proposals arrived after a firm 27.64% 1 year total shareholder return. The 30 day and 90 day share price returns of 4.18% and 4.67% suggest momentum has been building...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1585":"昨日强势股","BK4139":"生物科技","BK1587":"次新股","LENZ":"Therapeutics","BK4007":"制药","02171":"科济药业-B","BK4539":"次新股","BK1161":"生物科技"},"translate_title":"在2025年全年业绩和净亏损收窄后评估科济生物控股的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":0.9,"LENZ":1.5},"content_text":"CARsgen Therapeutics Holdings (SEHK:2171) moved after releasing full year 2025 results, reporting sales of CN¥125.66 million and a net loss of CN¥97.86 million, along with updated corporate governance proposals announced the same day. See our latest analysis for CARsgen Therapeutics Holdings. The earnings release and governance proposals arrived after a firm 27.64% 1 year total shareholder return. The 30 day and 90 day share price returns of 4.18% and 4.67% suggest momentum has been building despite a 5.54% 1 day pullback to HK$15.7. If this kind of biotech rerating has your attention, it can be useful to see what else is moving across healthcare and AI, starting with 124 healthcare AI stocks With CARsgen’s revenue of CN¥125.66 million, a narrowed net loss of CN¥97.86 million and a 1 year total return of 27.64%, you now have to ask whether there is still value on the table or the market is already pricing in future growth. AdvertisementPrice to Book of 9.8x: Is it justified? CARsgen trades on a P/B of 9.8x, which, against the latest close at HK$15.7, points to the market assigning a rich value to its equity base. P/B compares the market value of the company to its net assets, so a 9.8x reading means investors are paying almost ten times the book value per share. For a pre profit biotech focused on CAR T cell therapies, that level usually reflects expectations around the clinical pipeline and potential future cash generation rather than current profits. However, the current P/B sits well above both the peer group average of 5.4x and the Hong Kong biotech industry average of 4.8x. This suggests the market is pricing CARsgen at a premium compared to similar names. With no SWS fair P/B ratio available, there is no internal reference level for where that multiple might settle if expectations change. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 9.8x (OVERVALUED) However, there are clear risks, including the continued net loss of CN¥97.86 million and the possibility of CAR T trial or regulatory setbacks that could challenge today’s premium P/B. Find out about the key risks to this CARsgen Therapeutics Holdings narrative. Next Steps With mixed signals around valuation and risk, it helps to look at the full picture yourself and decide how comfortable you are with that trade off, starting with 2 key rewards and 1 important warning sign Looking for more investment ideas? If CARsgen has sharpened your focus on where to put fresh capital next, do not stop here. The wider market is full of other potential opportunities.  Target steadier growth potential by scanning companies that look cheap on quality metrics through the 219 high quality undervalued stocks. Build income strength into your portfolio by reviewing companies highlighted in the 466 dividend fortresses. Prioritise resilience by checking companies filtered by the 300 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620222709","isCrawlerRequest":true}